Literature DB >> 12180481

Tamoxifen-related porphyria cutanea tarda.

R Agarwal1, T J Peters, R C Coombes, D M Vigushin.   

Abstract

We report a case of porphyria cutanea tarda (PCT) in a patient with breast cancer following adjuvant tamoxifen. Cessation of tamoxifen resulted in a prompt decline in urinary porphyrins suggestive of a causative role. Tamoxifen is known to be hepatotoxic; however, its association with PCT is unclear. In this report, we discuss the porphyrinogenicity of tamoxifen and potential mechanisms.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12180481     DOI： 10.1385/MO:19:2:121

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  4 in total

1.  [Porphyria cutanea tarda after antineoplastic drugs].

Authors:  L Malina; H Michalíková; L Hussarová
Journal:  Cas Lek Cesk       Date:  1999-08-30

Review 2.  Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance.

Authors:  O F James; C P Day
Journal:  J Hepatol       Date:  1998-09       Impact factor: 25.083

3.  Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda.

Authors:  Z J Bulaj; J D Phillips; R S Ajioka; M R Franklin; L M Griffen; D J Guinee; C Q Edwards; J P Kushner
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

4.  Species differences in the covalent binding of [14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved.

Authors:  I N White; F De Matteis; A H Gibbs; C K Lim; C R Wolf; C Henderson; L L Smith
Journal:  Biochem Pharmacol       Date:  1995-04-18       Impact factor: 5.858
  4 in total
  1 in total

1.  Porphyria Cutanea Tarda Presenting with Scleroderma, Ichthyosis, Alopecia, and Vitiligo.

Authors:  Megan E MacGillivray; Thomas G Salopek
Journal:  Case Rep Dermatol       Date:  2018-05-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.